An appropriate vaccine is essential for a global pandemic preparedness and response. Hemagglutination inhibition assays reveal that the 2009 pandemic H1N1 viruses are antigenically homogeneous and distinct from currently circulating seasonal H1N1 viruses. Based on antigenic and genetic analysis and epidemiologic information, the WHO selected the A/California/7/2009 (H1N1) virus as the reference virus for vaccine development. We will evaluate the immunogenicity and infectivity of the live attenuated reassortant H1N1 virus containing the surface glycoproteins from the California/7/2009 (H1N1) virus and internal protein genes from the A/Ann Arbor/6/60 cold-adapted (ca) virus in clinical trials.

Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
2009
Total Cost
$42,347
Indirect Cost
City
State
Country
Zip Code
Jegaskanda, Sinthujan; Luke, Catherine; Hickman, Heather D et al. (2016) Generation and Protective Ability of Influenza Virus-Specific Antibody-Dependent Cellular Cytotoxicity in Humans Elicited by Vaccination, Natural Infection, and Experimental Challenge. J Infect Dis 214:945-52
Wright, Peter F; Hoen, Anne G; Ilyushina, Natalia A et al. (2016) Correlates of Immunity to Influenza as Determined by Challenge of Children with Live, Attenuated Influenza Vaccine. Open Forum Infect Dis 3:ofw108
Ilyushina, Natalia A; Haynes, Brenda C; Hoen, Anne G et al. (2015) Live attenuated and inactivated influenza vaccines in children. J Infect Dis 211:352-60
O'Donnell, Christopher D; Wright, Amber; Vogel, Leatrice et al. (2014) Humans and ferrets with prior H1N1 influenza virus infections do not exhibit evidence of original antigenic sin after infection or vaccination with the 2009 pandemic H1N1 influenza virus. Clin Vaccine Immunol 21:737-46
He, Xiao-Song; Sasaki, Sanae; Baer, Jane et al. (2013) Heterovariant cross-reactive B-cell responses induced by the 2009 pandemic influenza virus A subtype H1N1 vaccine. J Infect Dis 207:288-96
Sangster, Mark Y; Baer, Jane; Santiago, Felix W et al. (2013) B cell response and hemagglutinin stalk-reactive antibody production in different age cohorts following 2009 H1N1 influenza virus vaccination. Clin Vaccine Immunol 20:867-76